Evidence map›Paper›PMID 36430413›Full record

ArticleInternational journal of molecular sciences2022

Conjugates of Methylene Blue with Cycloalkaneindoles as New Multifunctional Agents for Potential Treatment of Neurodegenerative Disease.

Sergey O Bachurin, Elena F Shevtsova, Galina F Makhaeva, Alexey Yu Aksinenko, Vladimir V Grigoriev, Tatiana V Goreva, Tatiana A Epishina, Nadezhda V Kovaleva, Natalia P Boltneva, Sofya V Lushchekina and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Recent Advances in the Search for Effective Anti-Alzheimer's Drugs.International journal of molecular sciences · 2024
    Review
  5. New Hybrid Structures Based on Memanthine and Edaravone Molecules.Doklady. Biochemistry and biophysics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Sergey O BachurinInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.ORCID 0000-0003-3637-818X
Elena F ShevtsovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.ORCID 0000-0003-2887-1185
Galina F MakhaevaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.ORCID 0000-0002-8136-6906
Alexey Yu AksinenkoInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.ORCID 0000-0002-7281-9467
Vladimir V GrigorievInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Tatiana V GorevaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Tatiana A EpishinaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Nadezhda V KovalevaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.ORCID 0000-0002-4990-5068
Natalia P BoltnevaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.ORCID 0000-0002-7171-8832
Sofya V LushchekinaEmanuel Institute of Biochemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia.ORCID 0000-0002-6922-020X
Elena V RudakovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Darya V VinogradovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Pavel N ShevtsovInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.ORCID 0000-0001-5960-3680
Elena A PushkarevaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.ORCID 0000-0002-3550-1564
Ludmila G DubovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Tatiana P SerkovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Ivan M VeselovInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Vladimir P FisenkoDepartment of Pharmacology, Institute of Biodesign and Complex System Modelling, Biomedical Science & Technology Park, Sechenov I.M. First Moscow State Medical University, 119991 Moscow, Russia.
Rudy J RichardsonDepartment of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-2028-5723
Institute of Physiologically Active Compounds · RUInstitute of Biochemical Physics NM Emanuel · RUSechenov University · RUUniversity of Michigan · US

Funding

grant agreement (Moscow, October 1, 2020, Grant No. 075-15-2020-777) as government subsidies from the Federal budget of Russian Federation in accordance with paragraph 4 of article 78.1 of the Budget Code of the Russian Federation 075-15-2020-777
6 · The paper itself

Abstract

The development of multi-target-directed ligands (MTDLs) would provide effective therapy of neurodegenerative diseases (ND) with complex and nonclear pathogenesis. A promising method to create such potential drugs is combining neuroactive pharmacophoric groups acting on different biotargets involved in the pathogenesis of ND. We developed a synthetic algorithm for the conjugation of indole derivatives and methylene blue (

Indexed as

Alzheimer DiseaseNeurodegenerative DiseasesCalciumCholinesterase InhibitorsCholinesterasesHumansLigandsMethylene BlueReceptors, N-Methyl-D-AspartateCalciumCholinesterase InhibitorsCholinesterasesLigandsMethylene BlueReceptors, N-Methyl-D-Aspartatecholinesterasesconjugatescycloalkaneindolesmethylene bluemitochondriamultifunctional agentsneurodegenerative diseaseneuroprotectionNMDA-receptortubulin

Identifiers

PMID36430413
PMCPMC9697446
OpenAlexW4308973330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.